Zyvex current status and plans for atomically precise manufacturing

Tweet Zyvex is important for having stated the goal of creating molecular assemblers. James Von Ehr, CEO of Zyvex, has stated that his company has a ten-year plan to build a molecular assembler, that is, a machine system capable of atomically precise manufacturing at the nanoscale. Zyvex had an earlier, even more ambitious plan that they’ve had to revise. (In 2001, they had talked about raising and spending $300M over eight years). The new Zyvex approach will combine top-down work in nanolithography with bottom-up designs in scanning probe depositional chemistry.

Zyvex's Atomically Precised Manufacturing Project currently consists of three coordinated efforts: Micro Automation, Molecularly Precise Tools, and Patterned Atomic Layer Epitaxy.


Some info on how big Zyvex currently is people and moneywise.

http://www.nwaonline.net/articles/2005/10/07/business/01techconference.txt

Zyvex, which develops tools, material and products from molecular
nanotechnology, has gone from zero revenue three years ago to more
than 80 employees.

http://www.zyvex.com/News/pressreleases.html

July 2005
Zyvex announced financial results for our fiscal 2005 second quarter.
The Company continues to exceed expectations with total revenue for
the second quarter of $3.1 million — a 10 percent increase over plan
and a 70 percent increase over the same period in 2004.

Founded in 1997, Zyvex reported its first revenue in 2001, grossing
$150,000. Company revenue grew to $1.2 million in 2002, $4.3 million
in 2003, and $8.6 million in 2004. Gilmore anticipates that the
company will exceed $10 million in revenue during 2005, achieve
cash-flow break-even by Q1 2006, and become bottom-line profitable by
the end of 2006.

April 2005
Zyvex announced financial results for its fiscal 2005 first quarter on
April 14, 2005. The Company continues its business gains with total
revenues for the first quarter totaling $2.0 Million — a 240 percent
increase over the same period in 2004. International sales accounted
for 11 percent of the quarter's revenue.


My own estimates:
If 20% of revenues went to R&D, Plus grant money then
2004 $ 1.6M + 5M/year in grants
2005 $ 2-3M + 5M/year in grants
2006 $ 3-5M + 5M/year in grants